Edition:
India

People: Bausch Health Companies Inc (BHC.TO)

BHC.TO on Toronto Stock Exchange

32.77CAD
10:41pm IST
Change (% chg)

$0.67 (+2.09%)
Prev Close
$32.10
Open
$32.15
Day's High
$32.87
Day's Low
$32.09
Volume
443,324
Avg. Vol
858,988
52-wk High
$36.52
52-wk Low
$23.60

Ackermann, Christina 

Ms. Christina Ackermann is Executive Vice President, General Counsel of the Company. She has been our Executive Vice President and General Counsel since August 2016. Prior to joining Valeant, Ms. Ackermann was part of the Novartis group of companies for the past 14 years, most recently serving as Senior Vice President, General Counsel for Alcon, where she was responsible for the Legal, Intellectual Property and Compliance functions. Prior to this, she served as Global Head, Legal and General Counsel at Sandoz, the generics division of Novartis, from 2007 to 2012. She joined Novartis Pharma in 2002 as Head, Legal Technical Operations and Ophthalmics and assumed the role of Head Legal General Medicine in July 2005. Before Novartis, Ms. Ackermann served in Associate General Counsel roles with Bristol Myers Squibb and DuPont Pharmaceuticals, as well as in private practice, where she focused on securities and mergers & acquisitions. Ms. Ackermann has a Post Graduate Diploma in EC Competition Law from the University of London, U.K. and a Bachelor of Laws from Queen’s University, Kingston, Canada.

Basic Compensation

Total Annual Compensation, USD 600,000
Restricted Stock Award, USD 906,030
Long-Term Incentive Plans, USD --
All Other, USD 1,289,120
Fiscal Year Total, USD 2,795,150

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Joseph Papa

4,895,110

Paul Herendeen

2,597,950

Christina Ackermann

2,795,150

Thomas Appio

3,429,290

William Humphries

8,434,210

Thomas Ross

445,880
As Of  31 Dec 2017